[go: up one dir, main page]

CN119318697A - Integrins type enteral nutrition powder and preparation method thereof - Google Patents

Integrins type enteral nutrition powder and preparation method thereof Download PDF

Info

Publication number
CN119318697A
CN119318697A CN202411439533.XA CN202411439533A CN119318697A CN 119318697 A CN119318697 A CN 119318697A CN 202411439533 A CN202411439533 A CN 202411439533A CN 119318697 A CN119318697 A CN 119318697A
Authority
CN
China
Prior art keywords
parts
vitamin
mug
powder according
integrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411439533.XA
Other languages
Chinese (zh)
Inventor
易炳傑
易必祥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuji Le Xiamen Pharmaceutical Co ltd
Original Assignee
Fuji Le Xiamen Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Le Xiamen Pharmaceutical Co ltd filed Critical Fuji Le Xiamen Pharmaceutical Co ltd
Priority to CN202411439533.XA priority Critical patent/CN119318697A/en
Publication of CN119318697A publication Critical patent/CN119318697A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732—Pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pediatric Medicine (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及医用、牙科用或梳妆用的配制品技术领域，尤其涉及一种整蛋白型肠内营养粉剂及其制备方法。该粉剂包括以下重量份的原料：蛋白质12～20份、脂肪15～25份、碳水化合物55～65份、膳食纤维5～10份、低甲氧基果胶2～5份、复合维生素1～3份、矿物质2～4份、乳化剂0.1～1份、改性没食子酸0.001～0.005份以及水50～80份。本发明还提供了其制备方法。本发明制备的整蛋白型肠内营养粉剂营养全面、配比均衡、使用方便，不仅对提升患者营养状况有积极作用，还能够降低腹泻风险。The present invention relates to the technical field of preparations for medical, dental or cosmetic use, and in particular to a whole-protein enteral nutrition powder and a preparation method thereof. The powder comprises the following raw materials in parts by weight: 12 to 20 parts of protein, 15 to 25 parts of fat, 55 to 65 parts of carbohydrates, 5 to 10 parts of dietary fiber, 2 to 5 parts of low-methoxyl pectin, 1 to 3 parts of complex vitamins, 2 to 4 parts of minerals, 0.1 to 1 part of emulsifier, 0.001 to 0.005 parts of modified gallic acid and 50 to 80 parts of water. The present invention also provides a preparation method thereof. The whole-protein enteral nutrition powder prepared by the present invention is comprehensive in nutrition, balanced in proportion, and easy to use. It not only has a positive effect on improving the nutritional status of patients, but also can reduce the risk of diarrhea.

Description

Integrins type enteral nutrition powder and preparation method thereof
Technical Field
The invention relates to the technical field of medical, dental or dressing preparations, in particular to an integrin enteral nutrition powder and a preparation method thereof.
Background
Enteral nutrition (enteral nutrition, EN) refers to the injection of nutrients, which may be directly absorbed with or without chemical digestion, into the gastrointestinal tract of a patient, providing a means of nutritional support for the patient's desired nutrients. The integrin enteral nutrition preparation takes integrin or protein free matters as nitrogen sources, has good taste, can effectively stimulate the compensatory effect of intestinal tracts, and is suitable for patients with good gastrointestinal tract functions.
CN101804196A discloses a soybean-based integral enteral nutrition powder, each 100g of the product contains the following active ingredients of 14-19g of protein, 58-63g of carbohydrate, 16-22g of fat, 2-4g of compound vitamin and mineral substances and 0.6-1.2g of emulsifying agent, wherein the protein is mainly soybean isolated protein. The soybean-based whole protein enteral nutrition powder disclosed by the invention takes soybean protein as a main protein source, is supplemented with a small amount of casein, does not contain lactose, has complementary amino acid advantages in the two proteins, and is more beneficial to digestion and absorption of human bodies. The invention also provides a preparation method of the soybean-based integral enteral nutrition powder.
CN104256595A provides an integral enteral nutrition poly-polymerizing agent, the energy proportion is 12% -15% of protein, 25% -30% of fat and 55% -65% of carbohydrate. The invention can fully meet the requirements of human bodies, has comprehensive nutrition, balanced proportion and convenient use, has complementary advantages of all components, promotes each other, and has positive effects on improving the plasma protein level of patients and improving the nutrition condition of organisms. Is especially suitable for the nutrition support and the prevention and the treatment of malnutrition of various diseases such as operation period, critical patients and the like.
Enteral nutrition solutions have their benefits in clinical use, but are accompanied by some unavoidable problems. Mainly manifested by gastrointestinal discomfort such as nausea, emesis, abdominal distention, abdominal pain and diarrhea, and complications such as aspiration pneumonia, hyperglycemia, nasopharyngeal injury, sinusitis and otitis media. These adverse effects are often associated with the physical properties of the enteral nutritional solution. Due to the low viscosity of the nutritional liquid, normal physiological reactions cannot be produced in the body like solid foods. Long-term reliance on enteral nutrition may lead to intolerance by the body, causing a series of undesirable clinical problems. An integrin enteral nutritional powder is a special nutritional supplement product that is suitable for patients whose gastrointestinal function is present or partially present, but who are unable or unwilling to consume sufficient nutrition to meet physical demands by normal ingestion. The integrin enteral nutritional powder, although high in protein content, has several drawbacks including osmotic pressure problems, which can cause diarrhea or other gastrointestinal reactions if the enteral nutritional formulation has a high osmotic pressure. Osmotic pressure is determined by the solute in the solution, and high osmotic pressure solutions may result in reduced water absorption in the intestine, thereby causing diarrhea, formulation ingredients, ingredients in certain enteral nutritional powders, such as lactose or specific fat sources, may not be tolerated by certain patients, particularly patients who are lactose intolerant or have specific food sensitivity, which may result in dyspepsia and diarrhea, ingestion rates, if the enteral nutritional powder is ingested too fast or in excess, may exceed the absorption capacity of the intestine, resulting in unabsorbed ingredients entering the large intestine, causing diarrhea, and intestinal dysfunction, if the patient has intestinal dysfunction, such as too fast intestinal movement or poor intestinal absorption, the enteral nutritional powder may not be fully absorbed, causing diarrhea.
Disclosure of Invention
In view of the above-mentioned drawbacks of the prior art, the present invention provides an integrin enteral nutrition powder and a preparation method thereof.
Gallic acid is a natural compound with multiple pharmacological actions, and the potential of the gallic acid for preventing diarrhea is mainly attributed to the fact that firstly, the anti-inflammatory action of the gallic acid can inhibit the release of inflammatory factors and reduce intestinal inflammation, secondly, the anti-oxidation property of the gallic acid is helpful for scavenging free radicals and protecting intestinal cells from oxidative damage, furthermore, the antibacterial property of the gallic acid is helpful for inhibiting the growth of harmful bacteria and maintaining the balance of intestinal flora, furthermore, the gallic acid can be converted into tannic acid with astringing action in vivo and is helpful for reducing intestinal secretion and repairing damaged intestinal epithelial cells, and finally, the gallic acid can also improve the barrier function of the intestinal tract by regulating the intestinal flora. By combining these mechanisms of action, gallic acid is effective in preventing and alleviating diarrhea symptoms. However, gallic acid has poor solubility at normal temperature, which will greatly limit its application. According to the invention, the sodium caseinate is used for modifying the gallic acid, and is a safe and harmless thickening agent and emulsifying agent, so that the sodium caseinate is good in water solubility and safer than other modification modes. In addition, the emulsifying and thickening effects of the sodium caseinate are due to the fact that the sodium caseinate has hydrophilic and hydrophobic genes in the molecular structure, so that the sodium caseinate can be attracted with water and fatty substances to form stable emulsion, and the more uniform emulsifying state of the sodium caseinate is more beneficial to feeding and absorbing of patients. The invention achieves the aim of preventing diarrhea of patients by adding the modified gallic acid, and the grafted sodium caseinate used for modification has various amino acids required by human bodies and has high nutritive value, so that the invention not only can improve the defect of poor water solubility of the gallic acid, but also can improve the nutrition of the preparation and enhance emulsification. The low methoxy pectin can play a role in increasing the adsorption force to water, protecting the alimentary canal mucous membrane, reducing inflammatory reaction and the like, so that the prepared whole protein enteral nutrition powder is comprehensive in nutrition, balanced in proportion and convenient to use, has a positive effect on improving the nutritional condition of patients and can also reduce diarrhea risk.
The invention provides an integral enteral nutrition powder which comprises, by weight, 12-20 parts of protein, 15-25 parts of fat, 55-65 parts of carbohydrate, 5-10 parts of dietary fiber, 2-5 parts of low-methoxy pectin, 1-3 parts of compound vitamin, 2-4 parts of mineral substances, 0.1-1 part of emulsifying agent, 0.001-0.005 part of modified gallic acid and 50-80 parts of water.
Further, the protein is casein.
Further, the fat is obtained by mixing linseed oil and coconut oil according to a mass ratio of 1:1.
Further, the carbohydrate is maltodextrin.
Further, the dietary fiber is formed by mixing inulin and fructo-oligosaccharides in a mass ratio of 1:1.
Further, the compound vitamin comprises vitamin A, vitamin D, vitamin E, vitamin K 1, vitamin C, folic acid, vitamin B 1, vitamin B 2, vitamin B 6, vitamin B 12, nicotinic acid, pantothenic acid, biotin and choline.
Further, the content of active ingredients of the vitamin complex in the enteral nutrition powder is respectively 150-180 mug RE, 1-3 mug vitamin D, 2-5 mug alpha-TE, 1 -20 mug vitamin K, 13-15 mg vitamin C, 40-50 mug gDFE folic acid, 1 0.5.5-2 mug vitamin B 2 0.5.5-2 mug vitamin B 6 0.5.5-2 mug vitamin B 12 0.5.5-2 mug vitamin B, 2-5 mug nicotinic acid, 1-3 mg pantothenic acid, 10-15 mg biotin and 50-70 mg choline per 100 mug.
Further, the mineral comprises sodium, potassium, calcium, zinc, iron, magnesium, copper, manganese, phosphorus, iodine, selenium, chromium, molybdenum, fluorine.
Further, the content of active ingredients of the mineral in the enteral nutrition powder is 350-500 mg of sodium, 400-500 mg of potassium, 200-350 mg of calcium, 3-5 mg of zinc, 4-8 mg of iron, 50-100 mg of magnesium, 150-200 mug of copper, 100-150 mug of manganese, 150-200 mg of phosphorus, 20-40 mug of iodine, 15-20 mug of selenium, 10-20 mug of chromium, 30-40 mug of molybdenum and 1-2 mug of fluorine, wherein each 100g of the active ingredients respectively.
Further, the emulsifier is a phospholipid.
The preparation method of the modified gallic acid comprises the following steps:
dropwise adding gallic acid into thionyl chloride in the atmosphere of X1 and nitrogen, stirring for 1-2 hours at room temperature, and concentrating under reduced pressure for the next step;
And X2, adding sodium caseinate into water, stirring uniformly, adding tetrabutylammonium bromide, adding a sodium hydroxide aqueous solution to adjust the pH value to 8, adding methylene dichloride, stirring uniformly, adding the residue obtained in the step X1, continuously stirring for 0.5-1 h, keeping the pH value at 8-9 all the time, adding dilute hydrochloric acid to acidify until the pH value is=2-3 after stirring is finished, wherein precipitation appears, centrifuging, separating, washing the lower-layer precipitate by methanol and tetrahydrofuran, and freeze-drying to obtain the sodium caseinate.
Preferably, the preparation method of the modified gallic acid comprises the following steps:
Dropwise adding 3-4 parts by weight of gallic acid into 16-18 parts by weight of thionyl chloride in a nitrogen atmosphere, stirring for 1-2 hours at room temperature, and concentrating under reduced pressure for the next step;
And X2, adding 8-12 parts by weight of sodium caseinate into 200-300 parts by weight of water, uniformly stirring, adding 2-5 parts by weight of tetrabutylammonium bromide, adding aqueous solution of sodium hydroxide to adjust the pH to 8, adding 200-300 parts by weight of dichloromethane, uniformly stirring, adding 8-15 parts by weight of residues in the step X1, continuously stirring for 0.5-1 h, keeping the pH at 8-9 all the time, adding dilute hydrochloric acid after stirring until the pH is=2-3, carrying out acidification until precipitation appears, centrifuging, washing the lower precipitate by methanol and tetrahydrofuran, and freeze-drying to obtain the product.
A method for preparing an integrin enteral nutrition powder, comprising the following steps:
s1, adding protein, carbohydrate, dietary fiber and low-methoxy pectin into water, heating to 50-60 ℃, and uniformly stirring and mixing to obtain a water phase;
S2, heating the fat to 40-50 ℃, and uniformly stirring to obtain an oil phase;
s3, mixing the water phase and the oil phase, adding an emulsifier and modified gallic acid, homogenizing for 2 times under 25-30 MPa, and then sterilizing and spray drying to obtain powder;
S4, mixing the powder with the compound vitamin and mineral substances, and sub-packaging.
The invention has the beneficial effects that:
1. Compared with the prior art, the invention achieves the aim of preventing diarrhea of patients by adding the modified gallic acid, and the grafted modified sodium caseinate has various amino acids required by human bodies and has high nutritive value, so that the invention not only can improve the defect of poor water solubility of the gallic acid, but also can improve the nutrition of the preparation and enhance emulsification. The low methoxy pectin can play a role in increasing the adsorption force to water, protecting the mucous membrane of the digestive tract, reducing inflammatory reaction and the like.
2. The whole protein enteral nutrition powder prepared by the invention has comprehensive nutrition, balanced proportion and convenient use, has positive effects on improving the nutritional status of patients and can reduce diarrhea risk.
Detailed Description
Example 1
The preparation method of the integrin enteral nutrition powder comprises the following steps in parts by weight:
s1, adding 16 parts of casein, 60 parts of maltodextrin, 4 parts of inulin, 4 parts of fructo-oligosaccharide and 4 parts of low methoxy pectin into 65 parts of water, heating to 55 ℃, and uniformly stirring and mixing to obtain a water phase;
s2, heating 10 parts of linseed oil and 10 parts of coconut oil to 45 ℃, and uniformly stirring to obtain an oil phase;
S3, mixing the water phase and the oil phase, adding 0.5 part of phosphate and 0.003 part of modified gallic acid, homogenizing for 2 times under 25MPa, and then sterilizing and spray drying to obtain powder;
s4, mixing the powder with 2 parts of the compound vitamin and 3 parts of the mineral substances, and sub-packaging.
The content of active ingredients of the compound vitamin in the enteral nutrition powder is 160 mug RE, 2 mug vitamin D, 4 mug vitamin E, 1 mug vitamin K, 14 mug vitamin C, 45 mug folic acid DFE, 1 mg vitamin B, 2 mg vitamin B, 6 0.8.8 mg vitamin B 12 mg vitamin B, 4 mug nicotinic acid, 2 mug pantothenic acid, 12 mug vitamin H and 60 mug choline in each 100g enteral nutrition powder, and the content of active ingredients of the mineral in the enteral nutrition powder is 400 mug sodium, 450 mug potassium, 250 mug calcium, 5 mug zinc, 5 mug iron, 80 mug magnesium, 180 mug copper, 120 mug manganese, 160 mug phosphorus, 30 mug iodine, 18 mug selenium, 20 mug chromium, 35 mug molybdenum and 1 mug fluorine in each 100 g.
The preparation method of the modified gallic acid comprises the following steps of, by weight:
Dropwise adding 3.5 parts of gallic acid into 17 parts of thionyl chloride under the atmosphere of X1 and nitrogen, stirring for 1h at room temperature, and concentrating under reduced pressure for the next step;
And X2, adding 10.5 parts of sodium caseinate into 250 parts of water, uniformly stirring, adding 4 parts of tetrabutylammonium bromide, adding 1mol/L sodium hydroxide aqueous solution to adjust the pH to 8, adding 250 parts of dichloromethane, uniformly stirring, adding 10 parts of residues in the step X1, continuously stirring for 0.5h, keeping the pH at 8 all the time, adding 1mol/L dilute hydrochloric acid to acidify until the pH is=3 after stirring, centrifuging to separate precipitate, washing the lower precipitate by methanol and tetrahydrofuran, and freeze-drying to obtain the product.
Example 2
The essential difference was that the modified gallic acid was added in an amount of 0.001 parts, which was substantially the same as in example 1.
Example 3
The essential difference was that the modified gallic acid was added in an amount of 0.005 parts, which was substantially the same as in example 1.
Comparative example 1
The preparation method of the integrin enteral nutrition powder comprises the following steps in parts by weight:
s1, adding 16 parts of casein, 60 parts of maltodextrin, 4 parts of inulin, 4 parts of fructo-oligosaccharide and 4 parts of low methoxy pectin into 65 parts of water, heating to 55 ℃, and uniformly stirring and mixing to obtain a water phase;
s2, heating 10 parts of linseed oil and 10 parts of coconut oil to 45 ℃, and uniformly stirring to obtain an oil phase;
s3, mixing the water phase and the oil phase, adding 0.5 part of phosphate, homogenizing for 2 times under 25MPa, and then sterilizing and spray drying to obtain powder;
s4, mixing the powder with 2 parts of the compound vitamin and 3 parts of the mineral substances, and sub-packaging.
The content of active ingredients of the compound vitamin in the enteral nutrition powder is 160 mug RE, 2 mug vitamin D, 4 mug vitamin E, 1 mug vitamin K, 14 mug vitamin C, 45 mug folic acid DFE, 1 mg vitamin B, 2 mg vitamin B, 6 0.8.8 mg vitamin B 12 mg vitamin B, 4 mug nicotinic acid, 2 mug pantothenic acid, 12 mug vitamin H and 60 mug choline in each 100g enteral nutrition powder, and the content of active ingredients of the mineral in the enteral nutrition powder is 400 mug sodium, 450 mug potassium, 250 mug calcium, 5 mug zinc, 5 mug iron, 80 mug magnesium, 180 mug copper, 120 mug manganese, 160 mug phosphorus, 30 mug iodine, 18 mug selenium, 20 mug chromium, 35 mug molybdenum and 1 mug fluorine in each 100 g.
Comparative example 2
The preparation method of the integrin enteral nutrition powder comprises the following steps in parts by weight:
s1, adding 16 parts of casein, 60 parts of maltodextrin, 4 parts of inulin, 4 parts of fructo-oligosaccharide and 4 parts of low methoxy pectin into 65 parts of water, heating to 55 ℃, and uniformly stirring and mixing to obtain a water phase;
s2, heating 10 parts of linseed oil and 10 parts of coconut oil to 45 ℃, and uniformly stirring to obtain an oil phase;
s3, mixing the water phase and the oil phase, adding 0.5 part of phospholipid and 0.003 part of gallic acid, homogenizing for 2 times under 25MPa, and then sterilizing and spray drying to obtain powder;
s4, mixing the powder with 2 parts of the compound vitamin and 3 parts of the mineral substances, and sub-packaging.
The content of active ingredients of the compound vitamin in the enteral nutrition powder is 160 mug RE, 2 mug vitamin D, 4 mug vitamin E, 1 mug vitamin K, 14 mug vitamin C, 45 mug folic acid DFE, 1 mg vitamin B, 2 mg vitamin B, 6 0.8.8 mg vitamin B 12 mg vitamin B, 4 mug nicotinic acid, 2 mug pantothenic acid, 12 mug vitamin H and 60 mug choline in each 100g enteral nutrition powder, and the content of active ingredients of the mineral in the enteral nutrition powder is 400 mug sodium, 450 mug potassium, 250 mug calcium, 5 mug zinc, 5 mug iron, 80 mug magnesium, 180 mug copper, 120 mug manganese, 160 mug phosphorus, 30 mug iodine, 18 mug selenium, 20 mug chromium, 35 mug molybdenum and 1 mug fluorine in each 100 g.
Test example 1
SPF-grade BALB/C mice were selected and weighing 18-22g. The group of 10 animals is randomly divided into 6 groups, wherein the blank control group is filled with gastric physiological saline, and the experimental group is filled with gastric integrin type enteral nutrition powder. The group of mice were fed daily with the nutritional agent at a dose of 0.1mL/10g for 10 consecutive days. The mice were fed in a single cage during the stomach filling period, and the intake, water intake and wet feces weight were measured daily, and the weight was 1 time per 3d, and finally the food utilization factor was calculated according to the intake and the like, and the food utilization factor=wet feces weight/(intake+water intake) ×100%. The specific results are shown in Table 1.
TABLE 1 Effect of integrin enteral nutritional powder on food utilization factor in mice
Experimental protocol Food utilization coefficient/%
Example 1 21.35
Example 2 21.04
Example 3 21.21
Comparative example 1 20.54
Comparative example 2 20.78
Blank control group 17.12
The food utilization factor refers to the efficiency with which an animal obtains energy and nutrients from ingested food. This coefficient may reflect the digestion and absorption capacity of the animal for food. The food utilization coefficient can reflect the digestion and absorption capacity of the animal to the food, and is also related to the health condition of the animal, the type and quality of the food and other factors. Compared with a blank control group, the food utilization coefficient of the experimental group is obviously higher, so that the preparation of the experimental group can improve the food utilization coefficient of mice, is beneficial to digestion and absorption, and the prepared whole enteral nutrition powder has comprehensive nutrition, balanced proportion and convenient use and has positive effects on improving the nutritional status of patients.
Test example 2
80 SPF-class BALB/C mice are selected and randomly divided into 8 groups of 10 mice each, and a blank control group, a model group, a positive control group (Si Mida) and an experimental group are arranged. The animals of the other groups except the blank control group were all injected with the same amount of physiological saline in the abdominal cavity to cause severe diarrhea model by injecting the colibacillus liquid (0.3 mL/10 g) in the abdominal cavity. After 3 hours, the blank control group and the model group mice are infused with normal saline, the administration dose of each group of mice in the treatment group is 50mg/kg, and the Si Mida dose of the positive control group is 20mg/kg. After the experiment is started, diarrhea conditions of mice in 3h of intraperitoneal injection of escherichia coli injection, an internal model group and diarrhea conditions (including the rare stool frequency, the total stool frequency and the rare stool grade) of mice in each experimental group and a positive control group after administration are observed, and diarrhea indexes are calculated. The ratio of the number of loose stools to the total number of stools discharged by each mouse was calculated to obtain the loose stool rate. The degree of loose stool can be classified by the diameter of the loose stool polluted filter paper, and is classified into 4 grades, namely, the grade is less than 1cm and is 1 grade, the grade is 1-1.9 cm and is 2 grade, the grade is 2-3 cm and is 3 grade, and the grade is more than 3cm and is 4 grade. Diarrhea index = runny rate x average runny grade, average runny grade being the average of all runny grades.
Table 2 results of treatment of diarrhea mice with the whole enteral nutrition powder
The diarrhea index is an important index for evaluating the effect of anti-diarrhea drugs. By comparing the diarrhea index before and after administration, the treatment effect of the drug on diarrhea can be judged. As can be seen from comparison of a blank control group and a model group with an experimental group, the prepared integrin enteral nutrition powder has a certain treatment effect on diarrhea, probably because gallic acid has various potential mechanisms for treating diarrhea, reduces harmful bacteria in intestinal tracts through antibacterial action, reduces intestinal inflammation through antioxidant property, regulates intestinal flora to promote healthy microorganism growth, protects intestinal mucosa to reduce damage and regulates immune response to control inflammation, so that the diarrhea index of mice in the experimental group in examples 1-3 is obviously lower. The added gallic acid in comparative example 2 may limit the effect of gallic acid because the solubility of gallic acid at normal temperature is very poor, but in the examples, the added gallic acid is modified by sodium caseinate, and the sodium caseinate is a safe and harmless thickener and emulsifier, has very good water solubility and is safer than other modification modes. In addition, the emulsifying and thickening effects of sodium caseinate are due to the fact that the sodium caseinate has both hydrophilic and hydrophobic genes in the molecular structure, so that the sodium caseinate can be attracted with water and fatty substances to form stable emulsion, and the more uniform emulsifying state is more beneficial to feeding and absorbing of patients for enteral nutrition preparations. The low methoxy pectin can play a role in increasing the adsorption force to water, protecting the alimentary canal mucous membrane, reducing inflammatory reaction and the like, so that the prepared whole protein enteral nutrition powder is comprehensive in nutrition, balanced in proportion and convenient to use, has a positive effect on improving the nutritional condition of patients and can also reduce diarrhea risk. In examples 1 to 3, the effect of the addition amount of the modified gallic acid on the diarrhea index was shown to be a certain relationship, and example 1 was considered as the best one. Comparative example 1 has significantly higher diarrhea index than example 1, since no modified gallic acid was added.
Test example 3
The whole protein enteral nutrition powder developed by the invention is subjected to toxicology assessment according to GB 15193.1-2014 food safety national standard food safety toxicology assessment procedure. The evaluation included preliminary acute toxicity tests, genotoxicity tests, routine teratogenic experiments, and oral toxicity studies over a period of 90 days. The experimental result shows that no toxicity is found in the acute toxicity test, and the results are negative in the bone marrow cell micronucleus test, the mouse sperm malformation test and the 90-day oral toxicity test. These toxicology assessment results provide a scientific basis for the safety of the whole protein enteral nutrition powder.

Claims (10)

1. The integral enteral nutrition powder is characterized by comprising, by weight, 12-20 parts of protein, 15-25 parts of fat, 55-65 parts of carbohydrate, 5-10 parts of dietary fiber, 2-5 parts of low-methoxy pectin, 1-3 parts of compound vitamin, 2-4 parts of mineral substances, 0.1-1 part of emulsifying agent, 0.001-0.005 part of modified gallic acid and 50-80 parts of water.
2. The integrin enteral nutritional powder according to claim 1, wherein the protein is casein.
3. The integrin enteral nutritional powder according to claim 1, wherein the fat is linseed oil and coconut oil mixed in a mass ratio of 1:1.
4. The integrin enteral nutritional powder according to claim 1, wherein the carbohydrate is maltodextrin.
5. The enteral nutritional powder according to claim 1, wherein the dietary fiber is inulin mixed with fructooligosaccharides in a mass ratio of 1:1.
6. The enteral nutrition powder according to claim 1, wherein the vitamin complex comprises vitamin A, vitamin D, vitamin E, vitamin K 1, vitamin C, folic acid, vitamin B 1, vitamin B 2, vitamin B 6, vitamin B 12, niacin, pantothenic acid, biotin, choline.
7. The enteral nutritional powder according to claim 1 wherein the mineral comprises sodium, potassium, calcium, zinc, iron, magnesium, copper, manganese, phosphorus, iodine, selenium, chromium, molybdenum, fluorine.
8. The integrin enteral nutritional powder according to claim 1, wherein the emulsifier is a phospholipid.
9. The integrin enteral nutritional powder according to claim 1, wherein the preparation method of the modified gallic acid comprises the steps of:
dropwise adding gallic acid into thionyl chloride in the atmosphere of X1 and nitrogen, stirring for 1-2 hours at room temperature, and concentrating under reduced pressure for the next step;
And X2, adding sodium caseinate into water, stirring uniformly, adding tetrabutylammonium bromide, adding a sodium hydroxide aqueous solution to adjust the pH value to 8, adding methylene dichloride, stirring uniformly, adding the residue obtained in the step X1, continuously stirring for 0.5-1 h, keeping the pH value at 8-9 all the time, adding dilute hydrochloric acid to acidify until the pH value is=2-3 after stirring is finished, wherein precipitation appears, centrifuging, separating, washing the lower-layer precipitate by methanol and tetrahydrofuran, and freeze-drying to obtain the sodium caseinate.
10. A method for preparing the integrin enteral nutritional powder according to any one of claims 1-9, comprising the steps of:
s1, adding protein, carbohydrate, dietary fiber and low-methoxy pectin into water, heating to 50-60 ℃, and uniformly stirring and mixing to obtain a water phase;
S2, heating the fat to 40-50 ℃, and uniformly stirring to obtain an oil phase;
s3, mixing the water phase and the oil phase, adding an emulsifier and modified gallic acid, homogenizing for 2 times under 25-30 MPa, and then sterilizing and spray drying to obtain powder;
S4, mixing the powder with the compound vitamin and mineral substances, and sub-packaging.
CN202411439533.XA 2024-10-15 2024-10-15 Integrins type enteral nutrition powder and preparation method thereof Pending CN119318697A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411439533.XA CN119318697A (en) 2024-10-15 2024-10-15 Integrins type enteral nutrition powder and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202411439533.XA CN119318697A (en) 2024-10-15 2024-10-15 Integrins type enteral nutrition powder and preparation method thereof

Publications (1)

Publication Number Publication Date
CN119318697A true CN119318697A (en) 2025-01-17

Family

ID=94231605

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202411439533.XA Pending CN119318697A (en) 2024-10-15 2024-10-15 Integrins type enteral nutrition powder and preparation method thereof

Country Status (1)

Country Link
CN (1) CN119318697A (en)

Similar Documents

Publication Publication Date Title
JP6285108B2 (en) Probiotics in pre-operative and / or post-operative environments
EP0483070B1 (en) Nutritionally complete feeding composition containing hydrolysed soluble fiber
EP2337572B1 (en) Nutritional composition to promote healthy development and growth
CN100448451C (en) Nutritional compositions with contain slightly negatively charged, non-digestible polysaccharides and use thereof for reducing transport through tight junctions
EP1414316B1 (en) Nutritional composition preventing bacterial overgrowth
CN107467193B (en) A powder food based on goat milk for special medical use and its preparation method
CN119318697A (en) Integrins type enteral nutrition powder and preparation method thereof
KR102000170B1 (en) Food compositions for reducing body fat and improving intestinal function
CN107156481A (en) A kind of feed addictive for preventing and treating grice diarrhoea and preparation method thereof
CN114949202B (en) A composition of probiotics and protein and its application against Helicobacter pylori
WO2014134830A1 (en) Edible composition, food product comprising same, and preparation method for the food product
JP3285959B2 (en) Liquid preparation nutritional food for long-term medical care patients
CN1434681A (en) Method for maintaining on improving the synthesis of mucins
CN116548608B (en) Full-nutrition formula powder for children and preparation method and application thereof
CN109645466A (en) A kind of composition for pediatric tumor edible for patients
CN115006432B (en) Probiotic composition for resisting helicobacter pylori
CN120092950A (en) A nutritional composition for promoting immune function recovery in patients undergoing gastric volume reduction surgery
CN112753776A (en) Milk powder for protecting intestines and stomach and preparation method thereof
CN115737688A (en) Probiotics product capable of inhibiting and killing helicobacter pylori
CN120078147A (en) W1/O/W2Double-layer emulsion and preparation method and application thereof
JP2022126152A (en) Supplement and pet feed containing the same
CN119950564A (en) Application of a selenium-enriched Lactobacillus rhamnosus agent in the preparation of a drug for improving ulcerative colitis
CN118452385A (en) Lactic acid bacteria solid beverage and preparation method thereof
CN119214189A (en) Children's formula milk powder and its preparation method and application
Horowitz Promoting gut health with probiotics: living medicines for treating digestive disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination